Name
ICD-O-3 Morphology
Effective
2001 and later
Reportable
for cases diagnosed
2001 and later
Primary Site(s)
C379,
C383
Do not assign this histology just because the mediastinum is involved. Only assign this histology when the diagnosis is stated as “primary mediastinal."
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Code the primary site to C379 (thymus) or C383 (mediastinum) based on the physician's statement. For either thymus or mediastinal primaries, the mediastinal and cervical lymph nodes may be involved.
PMBL most likely arises within the thymus. Patients present with a localized anterosuperior mediastinal mass. The mass is often bulky and frequently invades adjacent structures such as lungs, pleura, or pericardium. Spread to supraclavicular and cervical LN can occur.
Workup should be done to exclude a secondary mediastinal involvement by a DLBCL versus a primary mediastinal B-cell lymphoma through the absence of bone marrow involvement and lymph node involvement outside of the region.
PMBL most likely arises within the thymus. Patients present with a localized anterosuperior mediastinal mass. The mass is often bulky and frequently invades adjacent structures such as lungs, pleura, or pericardium. Spread to supraclavicular and cervical LN can occur.
Workup should be done to exclude a secondary mediastinal involvement by a DLBCL versus a primary mediastinal B-cell lymphoma through the absence of bone marrow involvement and lymph node involvement outside of the region.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Med-DLBCL
PMBL
Definition
Primary mediastinal (thymic) large B-cell lymphoma (PMBL) is a mature aggressive large B-cell lymphoma (LBCL) of putative thymic B-cell origin arising in the mediastinum, with distinctive clinical, immunophenotypic, genotypic, and molecular features. Cases that arise outside the mediastinum are probably very uncommon, and cannot be confidently recognized without gene expression profiling studies.
Definitive Diagnostic Methods
Genetic testing
Histologic confirmation
Immunophenotyping
Genetics Data
CIITA at 16p13.13
Immunoglobulin genes clonally rearranged
PDCD1LG1 (also called CF274 or PDL1)
PDCD1LG2 (also called PDL2)
9p24.1
Immunophenotyping
BOB1+ (expression/positive)
CD19+ (expression/positive)
CD20+ (expression/positive)
CD22+ (expression/positive)
CD30+ (expression/weakly positive) and heterogeneous
CD79a+ (expression/positive)
Ig functional gene arrangement
Immunoglobulin- (no expression/lacking/negative)
OCT2+ (expression/positive)
PAX5+ (expression/positive)
PU1+ (expression/positive)
Treatments
Chemotherapy
Radiation therapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
200.7 Large cell lymphoma
Corresponding ICD-10 Codes
C83.8 Other types of diffuse non-Hodgkin lymphoma
Corresponding ICD-10-CM Codes (U.S. only)
C85.2 Mediastinal (thymic) large B-cell lymphoma (effective October 01, 2015)
Signs and Symptoms
Drenching night sweats
Fatigue
Fever (for no known reason)
Localized anterosuperior mediastinal mass
Pain in the chest, abdomen, or bones (for no known reason)
Painless swelling in the lymph nodes
Skin rash or itchy skin
Weight loss (for no known reason)
Diagnostic Exams
Blood chemistry studies
Bone marrow aspiration and biopsy
CT (CAT) scan
Cytogenetic analysis
Flow cytometry
Immunohistochemistry
Immunophenotyping
Laparoscopy (rarely performed)
Laparotomy (rarely performed)
Lymph node biopsy
PET (positron emission tomography) scan
Progression and Transformation
None
Epidemiology and Mortality
Age: 35 years median age (occurs predominantly in young adults)
Incidence: 2-4% of non-Hodgkin lymphomas
Sex: female predominance
Survival: beyond 2 years
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 314-316
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 314-316
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq